FDA approves Merck's new Capvaxive vaccine for adults, expected to boost market share

From CNBC: 2024-06-17 17:48:26

The FDA approved Merck’s new Capvaxive vaccine to protect adults from pneumococcus bacteria, preventing illnesses like pneumonia. Healthy adults and those with chronic conditions are at risk. Around 150,000 adults in the U.S. are hospitalized yearly with invasive pneumococcal disease, with the highest death rates in adults 50 and above.

Merck’s competitive edge in the $7 billion pneumococcal vaccine market is expected to grow to over $10 billion. Capvaxive can surpass Pfizer’s Prevnar 20 with data showing protection against 8 extra strains of pneumococcus bacteria. Merck aims for rapid uptake of their single-dose vaccine for adults, potentially offsetting losses from Keytruda.



Read more at CNBC: FDA approves Merck pneumococcal disease vaccine designed for adults